Press Releases

• Net sales of $1.86 billion, increase of 1.2%; core organic net sales growth of 7.8%
• Net income of $167.0 million; Adjusted EBITDA of $384.0 million
• Diluted GAAP EPS of $0.25; adjusted EPS of $0.34
• Operating cash flow of $258.3 million; free cash flow of $219.3 million
• Adjusted net leverage reduced to 3.6X, down 0.6X year-to-date

RADNOR, Pa., Oct. 28, 2022 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today reported financial results for the quarter ended September 30, 2022.

"In the third quarter, we delivered 7.8% core organic revenue growth and more than 100 basis points in Adjusted EBITDA margin expansion. Our results benefited from approximately 30% core organic growth in bioproduction and double-digit core organic growth in advanced technologies and applied materials. We continue to execute on our long-term strategy through innovation and capacity investments that will strengthen our platform and enable sustained growth," said Michael Stubblefield, President and Chief Executive Officer of Avantor.

"We are focused on improving the performance of our recent acquisitions and leveraging our channel to accelerate commercial synergies. We are excited by the enhanced capabilities they bring and are confident in realizing the long-term potential of these assets."

"Looking ahead, we expect continued strength in our core business, despite some near-term headwinds. We have updated our full-year guidance to reflect our third quarter performance, $400 million of revenue from our 2021 acquisitions, changes to foreign exchange rates and current market conditions. We now expect to deliver 2.5% - 3.0% organic growth (6.0% - 6.5% excluding COVID-19 headwinds) and $1.38 to $1.40 of adjusted EPS for the full year. We remain confident that the strength of our end markets and the resilience of our model will position us for continued success," Stubblefield concluded.

For the three months ended September 30, 2022, net sales were $1.86 billion, an increase of 1.2% compared to the third quarter of 2021. Foreign currency translation had an unfavorable impact of 5.8% with M&A adding 2.5%, resulting in organic sales growth of 4.5% and core organic sales growth of 7.8%. Net income increased to $167.0 million from $156.8 million in the third quarter of 2021 and adjusted net income was up 8.8% from the comparable prior period, excluding foreign exchange headwinds. Adjusted EBITDA increased 6.9% to $384.0 million, and Adjusted EBITDA margin expanded by more than 100 basis points to 20.7%, as compared to 19.6% in the comparable prior period. 

Diluted earnings per share on a GAAP basis was $0.25, while adjusted EPS was $0.34.

Operating cash flow in the quarter was $258.3 million, while free cash flow in the quarter was $219.3 million.

Adjusted net leverage was 3.6X as of September 30, 2022, down from 3.9X as of June 30, 2022, and in line with our target leverage of 2X - 4X.

Management uses Adjusted EBITDA to measure and evaluate the internal operating performance of the Company's business segments. Adjusted EBITDA is also our segment reporting profitability measure under generally accepted accounting principles.

• Net sales were $1,123.2 million, a reported increase of 7.5%, as compared to $1,045.0 million in the third quarter of 2021. Core organic sales increased 8.8%.
• Adjusted EBITDA margin increased approximately 80 basis points to 23.4%, as compared to 22.6% in the comparable prior period.

• Net sales were $595.1 million, a reported decrease of 11.8%, as compared to $674.7 million in the third quarter of 2021. Core organic sales increased 4.8%.
• Adjusted EBITDA margin increased approximately 180 basis points to 21.9%, as compared to 20.1% in the comparable prior period.

• Net sales were $138.2 million, a reported increase of 20.6%, as compared to $114.6 million in the third quarter of 2021. Core organic sales increased 15.1%.
• Adjusted EBITDA margin increased approximately 10 basis points to 25.8%, as compared to 25.7% in the comparable prior period.

Avantor will host a conference call to discuss its results today, October 28, at 8:00 a.m. Eastern Daylight Time. A live webcast can be accessed on the investors section of Avantor's website.  

Following the live webcast, a replay of the webcast and the slide presentation will be available at https://ir.avantorsciences.com/investors/news-and-events/events/default.aspx.

Avantor^®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.

To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles ("GAAP") with certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measures should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measures, and such measures may not be comparable to similarly titled measures reported by other companies. Rather, these measures should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage investors to review our consolidated financial statements included in reports filed with the SEC in their entirety and not rely solely on any one, single financial measurement or communication.

The non-GAAP financial measures used in this press release are sales growth on an organic basis, sales growth on a core organic basis, Adjusted EBITDA, adjusted net income, adjusted EPS, adjusted net leverage and free cash flow.

• Sales growth on an organic basis eliminates from our reported net sales growth the impacts of earnings from any acquired or disposed businesses that have been owned for less than one year and changes in foreign currency exchange rates. Sales growth on a core organic basis eliminates from our organic growth the impacts of any COVID-19 related net sales. We believe that these measurements are useful as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented.
  
  
• Adjusted EBITDA is to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. We believe that this measurement is useful as a way to analyze the underlying trends in our business consistently across the periods presented.
  
  
• Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) net foreign currency remeasurement gains or losses relating to financing activities, (iii) losses on extinguishment of debt, (iv) other costs or credits that are either isolated or cannot be expected to recur with any regularity or predictability. From this amount, we then add or subtract an assumed incremental income tax impact on the above noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measurement is useful as a way to analyze the business consistently across the periods presented.
  
  
• Beginning with the quarter ended March 31, 2022, Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count. Prior to the first quarter of 2022, Adjusted EPS was our adjusted net income divided by the normalized shares outstanding. The normalized shares outstanding reflected for all periods (i) the total number of shares of common stock outstanding following our initial public offering, plus (ii) the dilutive effect of the assumed exercise or conversion of instruments (including our 6.250% Series A mandatory convertible preferred stock assuming the lowest rate of conversion into common stock). We believe that this measurement is an additional way to analyze the underlying trends in our business consistently across the periods presented.
  
  
• Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions as if those acquisitions had occurred on the first day of the trailing 12-month period). We believe that this measurement is a useful way to evaluate and measure the Company's capital allocation strategies and the underlying trends in the business.
  
  
• Free cash flow is equal to our cash flow from operating activities, excluding acquisition-related costs paid in the period, less capital expenditures. We believe that this measurement is useful as it provides a view on the Company's ability to generate cash for use in financing or investment activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "estimate," "expect," "forecast," "intend," "likely," "outlook," "plan," "potential," "project," "projection," "seek," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com

Media Contact
Petro Kacur
Director, PR and External Communications
Avantor
404-408-0663
Petro.Kacur@avantorsciences.com 

SOURCE Avantor and Financial News